Long-lasting immunotherapy response in stage IV lung cancer with brain metastasis
“In the last decade, immunotherapy agents changed the treatment landscape for Non-Small Cell Lung Cancer (NSCLC).”
BUFFALO, NY - October 18, 2024 – A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis.”
As highlighted in the abstract of this report, approximately 20% of lung cancer patients have brain metastases at diagnosis, which is associated with a worse prognosis and negatively impacts quality ...














